Oaktree Capital Management LP Buys Shares of 179,593 Mesoblast Limited (NASDAQ:MESO)

Oaktree Capital Management LP purchased a new position in shares of Mesoblast Limited (NASDAQ:MESO) in the fourth quarter, Holdings Channel.com reports. The fund purchased 179,593 shares of the company’s stock, valued at approximately $3,556,000.

Several other institutional investors have also recently made changes to their positions in the company. R Squared Ltd acquired a new stake in Mesoblast during the fourth quarter worth $30,000. Lindbrook Capital LLC increased its position in shares of Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after purchasing an additional 901 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Mesoblast in the 4th quarter valued at about $50,000. GAMMA Investing LLC lifted its position in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after buying an additional 1,213 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Mesoblast during the fourth quarter worth about $134,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Piper Sandler restated an “overweight” rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Stock Performance

Shares of MESO stock opened at $12.11 on Friday. The firm has a 50 day moving average of $16.31 and a two-hundred day moving average of $13.16. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast Limited has a 52 week low of $4.60 and a 52 week high of $22.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.